Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.

Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, Yancy CW, Heidenreich PA, Hernandez AF.

J Am Heart Assoc. 2017 Dec 23;6(12). pii: e006540. doi: 10.1161/JAHA.117.006540.

2.

Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.

Lam PH, Dooley DJ, Inampudi C, Arundel C, Fonarow GC, Butler J, Wu WC, Blackman MR, Anker MS, Deedwania P, White M, Prabhu SD, Morgan CJ, Love TE, Aronow WS, Allman RM, Ahmed A.

Int J Cardiol. 2017 Jan 15;227:462-466. doi: 10.1016/j.ijcard.2016.11.006. Epub 2016 Nov 4.

3.

Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).

Inampudi C, Parvataneni S, Morgan CJ, Deedwania P, Fonarow GC, Sanders PW, Prabhu SD, Butler J, Forman DE, Aronow WS, Allman RM, Ahmed A.

Am J Cardiol. 2014 Jul 1;114(1):79-82. doi: 10.1016/j.amjcard.2014.03.062. Epub 2014 Apr 18.

4.

Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.

Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH.

JAMA. 2012 Nov 28;308(20):2097-107. doi: 10.1001/jama.2012.14795.

PMID:
23188026

Supplemental Content

Loading ...
Support Center